Given that the standard-of-care for many ER+/HER2− breast cancers is now hormone therapy in combination with a CDK4/6 inhibitor, there is a strong rationale to suggest inhibitors of PI3K/mTOR signaling may also be active in this arena. This evidence concerns the gene MTOR and breast carcinoma.